{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:21:00Z","timestamp":1787750460613,"version":"build-2784847793"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>\n                    <jats:italic toggle=\"yes\">Enhancer of Zeste Homolog 2 (EZH2)<\/jats:italic>\n                    , the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2), mediates histone H3 lysine 27 trimethylation (H3K27me3) and plays an important role in epigenetic transcriptional repression and oncogenesis. Although\n                    <jats:italic toggle=\"yes\">EZH2<\/jats:italic>\n                    mutations are well characterized in B-cell lymphomas, its role in cutaneous T-cell lymphomas, including mycosis fungoides (MF), remains incompletely understood. The aim of this study was to evaluate\n                    <jats:italic toggle=\"yes\">EZH2<\/jats:italic>\n                    expression in MF using immunohistochemistry and to investigate its association with clinicopathologic parameters and proliferative activity. A total of 46 patients with MF were retrospectively analyzed. The cohort comprised 41 patients with early-stage disease (IA\u2013IB) and 5 patients with more advanced disease manifestations (plaque and tumor lesions, including stage IIB cases). Nuclear\n                    <jats:italic toggle=\"yes\">EZH2<\/jats:italic>\n                    expression was semiquantitatively scored, and the Ki-67 proliferation index was assessed. Associations between\n                    <jats:italic toggle=\"yes\">EZH2<\/jats:italic>\n                    expression and clinicopathologic variables were analyzed using nonparametric statistical tests, including the Kruskal\u2013Wallis and Spearman correlation tests.\n                    <jats:italic toggle=\"yes\">EZH2<\/jats:italic>\n                    expression increased progressively with advancing disease stage and lesion morphology (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.05). A significant positive correlation was observed between\n                    <jats:italic toggle=\"yes\">EZH2<\/jats:italic>\n                    expression and disease stage (r = 0.342;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.02), and with the Ki-67 proliferation index (r = 0.575;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.001).\n                    <jats:italic toggle=\"yes\">EZH2<\/jats:italic>\n                    expression showed no significant association with serum lactate dehydrogenase levels, \u03b2\n                    <jats:sub>2<\/jats:sub>\n                    -microglobulin levels, age, sex, or disease duration. The relatively small sample size, particularly the limited number of advanced-stage cases, and the retrospective design represent study limitations. These findings demonstrate that\n                    <jats:italic toggle=\"yes\">EZH2<\/jats:italic>\n                    expression parallels disease progression and proliferative activity in MF and suggest that\n                    <jats:italic toggle=\"yes\">EZH2<\/jats:italic>\n                    immunohistochemistry may serve as a useful adjunct marker reflecting biological disease activity in routine dermatopathologic evaluation.\n                  <\/jats:p>","DOI":"10.1097\/dad.0000000000003316","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:00:24Z","timestamp":1782457224000},"page":"705-709","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["EZH2 Upregulation Reflects Proliferation and Disease Stage in Mycosis Fungoides"],"prefix":"10.1097","volume":"48","author":[{"given":"Asl\u0131","family":"Aksu","sequence":"first","affiliation":[{"name":"Department of DermatologyUniversity of Health Sciences, \u015ei\u015fli Hamidiye Etfal Training and Research HospitalSeyrantepe, \u0130stanbul Turkey; and,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Alt\u0131nel","sequence":"additional","affiliation":[{"name":"Department of PathologyUniversity of Health Sciences, \u015ei\u015fli Hamidiye Etfal Training and Research HospitalSeyrantepe, \u0130stanbul Turkey.,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semih","family":"Arslan","sequence":"additional","affiliation":[{"name":"Department of DermatologyUniversity of Health Sciences, \u015ei\u015fli Hamidiye Etfal Training and Research HospitalSeyrantepe, \u0130stanbul Turkey; and,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayberk","family":"Aktaran","sequence":"additional","affiliation":[{"name":"Department of DermatologyUniversity of Health Sciences, \u015ei\u015fli Hamidiye Etfal Training and Research HospitalSeyrantepe, \u0130stanbul Turkey; and,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar Ozdemir","family":"Cetinkaya","sequence":"additional","affiliation":[{"name":"Department of DermatologyUniversity of Health Sciences, \u015ei\u015fli Hamidiye Etfal Training and Research HospitalSeyrantepe, \u0130stanbul Turkey; and,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birg\u00fcl \u00d6zkesici","family":"Kurt","sequence":"additional","affiliation":[{"name":"Department of DermatologyUniversity of Health Sciences, \u015ei\u015fli Hamidiye Etfal Training and Research HospitalSeyrantepe, \u0130stanbul Turkey; and,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazel Ezgi","family":"Kaya","sequence":"additional","affiliation":[{"name":"Department of DermatologyUniversity of Health Sciences, \u015ei\u015fli Hamidiye Etfal Training and Research HospitalSeyrantepe, \u0130stanbul Turkey; and,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lknur","family":"Altunay","sequence":"additional","affiliation":[{"name":"Department of DermatologyUniversity of Health Sciences, \u015ei\u015fli Hamidiye Etfal Training and Research HospitalSeyrantepe, \u0130stanbul Turkey; and,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"R1-20260819","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1200\/JCO.2000.18.15.2908","article-title":"Primary cutaneous T-cell lymphoma: review and current concepts","volume":"18","author":"Siegel","year":"2000","journal-title":"J Clin Oncol"},{"key":"R2-20260819","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/cancers13081931","article-title":"Mycosis fungoides and s\u00e9zary syndrome: an integrative review","volume":"13","author":"Garc\u00eda-D\u00edaz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R3-20260819","doi-asserted-by":"crossref","first-page":"1043254","DOI":"10.3389\/fonc.2022.1043254","article-title":"Advances in the understanding and treatment of cutaneous T-cell lymphoma","volume":"12","author":"Bakr","year":"2022","journal-title":"Front Oncol"},{"key":"R4-20260819","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R5-20260819","doi-asserted-by":"crossref","first-page":"1233953","DOI":"10.3389\/fonc.2023.1233953","article-title":"Non-canonical functions of EZH2 in cancer","volume":"13","author":"Zimmerman","year":"2023","journal-title":"Front Oncol"},{"key":"R6-20260819","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-019-0814-6","article-title":"EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications","volume":"12","author":"Li","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R7-20260819","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood.2019004256","article-title":"Genetic and epigenetic insights into cutaneous T-cell lymphoma","volume":"139","author":"Tensen","year":"2022","journal-title":"Blood"},{"key":"R8-20260819","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutation of EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"key":"R9-20260819","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"B\u00f6d\u00f6r","year":"2013","journal-title":"Blood"},{"key":"R10-20260819","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.3390\/biomedicines9121842","article-title":"Divergent effects of EZH1 and EZH2 protein expression on the prognosis of patients with T-cell lymphomas","volume":"9","author":"Sch\u00fcmann","year":"2021","journal-title":"Biomedicines"},{"key":"R11-20260819","doi-asserted-by":"crossref","first-page":"adv00230","DOI":"10.2340\/00015555-3578","article-title":"Stage-dependent increase in expression of microRNA-155 and Ki-67 and number of tumour-associated inflammatory cells in folliculotrophic mycosis fungoides","volume":"100","author":"Atzmony","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"R13-20260819","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.3390\/ijms23073538","article-title":"Epigenetics of cutaneous T-cell lymphomas","volume":"23","author":"Hara","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R14-20260819","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7603\/s40681-014-0001-6","article-title":"EZH2: novel therapeutic target for human cancer","volume":"4","author":"Li","year":"2014","journal-title":"Biomedicine (Taipei)"},{"key":"R15-20260819","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13148-020-00962-x","article-title":"Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma","volume":"12","author":"Zhang","year":"2020","journal-title":"Clin Epigenetics"},{"key":"R16-20260819","doi-asserted-by":"crossref","first-page":"34","DOI":"10.20892\/j.issn.2095-3941.2020.0216","article-title":"Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials","volume":"18","author":"Lai","year":"2021","journal-title":"Cancer Biol Med"},{"key":"R17-20260819","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jid.2017.10.036","article-title":"Dual role of EZH2 in cutaneous anaplastic large cell lymphoma: promoting tumor cell survival and regulating tumor microenvironment","volume":"138","author":"Yi","year":"2018","journal-title":"J Invest Dermatol"},{"key":"R18-20260819","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"key":"R19-20260819","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"key":"R20-20260819","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.2022016862","article-title":"An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma","volume":"141","author":"Izutsu","year":"2023","journal-title":"Blood"},{"key":"R21-20260819","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S1470-2045(24)00503-5","article-title":"Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study","volume":"25","author":"Zinzani","year":"2024","journal-title":"Lancet Oncol"},{"key":"R22-20260819","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S1470-2045(24)00502-3","article-title":"Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study","volume":"25","author":"Maruyama","year":"2024","journal-title":"Lancet Oncol"},{"key":"R23-20260819","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/imcb.12748","article-title":"Unlocking adult T-cell leukemia\/lymphoma's epigenetic secrets: delving into the mechanism and impact of EZH1\/2 inhibition","volume":"102","author":"Tavakoli Shirazi","year":"2024","journal-title":"Immunol Cell Biol"},{"key":"R24-20260819","doi-asserted-by":"crossref","first-page":"103398","DOI":"10.1016\/j.eclinm.2025.103398","article-title":"Safety and efficacy of HH2853, a novel EZH1\/2 dual inhibitor, in patients with refractory solid tumours or Non-Hodgkin lymphomas: a phase I study","volume":"86","author":"Fan","year":"2025","journal-title":"EClinicalMedicine"},{"key":"R25-20260819","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ccell.2025.01.013","article-title":"EZH1\/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models","volume":"43","author":"Porazzi","year":"2025","journal-title":"Cancer Cell"},{"key":"R26-20260819","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1016\/j.celrep.2018.05.050","article-title":"Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity","volume":"23","author":"Wang","year":"2018","journal-title":"Cell Rep"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/DAD.0000000000003316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:34:37Z","timestamp":1787747677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/DAD.0000000000003316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000003316","relation":{},"ISSN":["0193-1091","1533-0311"],"issn-type":[{"value":"0193-1091","type":"print"},{"value":"1533-0311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]}}}